These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11173159)

  • 1. Hypoxia in human intraperitoneal and extremity sarcomas.
    Evans SM; Hahn SM; Magarelli DP; Zhang PJ; Jenkins WT; Fraker DL; Hsi RA; McKenna WG; Koch CJ
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):587-96. PubMed ID: 11173159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EF5 binding and clinical outcome in human soft tissue sarcomas.
    Evans SM; Fraker D; Hahn SM; Gleason K; Jenkins WT; Jenkins K; Hwang WT; Zhang P; Mick R; Koch CJ
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):922-7. PubMed ID: 16458778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode.
    Jenkins WT; Evans SM; Koch CJ
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):1005-17. PubMed ID: 10705024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of hypoxia in human squamous cell carcinoma by EF5 binding.
    Evans SM; Hahn S; Pook DR; Jenkins WT; Chalian AA; Zhang P; Stevens C; Weber R; Weinstein G; Benjamin I; Mirza N; Morgan M; Rubin S; McKenna WG; Lord EM; Koch CJ
    Cancer Res; 2000 Apr; 60(7):2018-24. PubMed ID: 10766193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.
    Lee J; Siemann DW; Koch CJ; Lord EM
    Int J Cancer; 1996 Jul; 67(3):372-8. PubMed ID: 8707411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide].
    Evans SM; Joiner B; Jenkins WT; Laughlin KM; Lord EM; Koch CJ
    Br J Cancer; 1995 Oct; 72(4):875-82. PubMed ID: 7547234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients.
    Busch TM; Hahn SM; Wileyto EP; Koch CJ; Fraker DL; Zhang P; Putt M; Gleason K; Shin DB; Emanuele MJ; Jenkins K; Glatstein E; Evans SM
    Clin Cancer Res; 2004 Jul; 10(14):4630-8. PubMed ID: 15269134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies.
    Woods ML; Koch CJ; Lord EM
    Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):93-101. PubMed ID: 12118570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors.
    Mahy P; De Bast M; Gallez B; Gueulette J; Koch CJ; Scalliet P; Grégoire V
    Radiother Oncol; 2003 Apr; 67(1):53-61. PubMed ID: 12758240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
    Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
    J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding.
    Evans SM; Judy KD; Dunphy I; Jenkins WT; Nelson PT; Collins R; Wileyto EP; Jenkins K; Hahn SM; Stevens CW; Judkins AR; Phillips P; Geoerger B; Koch CJ
    Cancer Res; 2004 Mar; 64(5):1886-92. PubMed ID: 14996753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome.
    Evans SM; Du KL; Chalian AA; Mick R; Zhang PJ; Hahn SM; Quon H; Lustig R; Weinstein GS; Koch CJ
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1024-31. PubMed ID: 17967299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors.
    Evans SM; Jenkins WT; Joiner B; Lord EM; Koch CJ
    Cancer Res; 1996 Jan; 56(2):405-11. PubMed ID: 8542599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation.
    Evans SM; Hahn SM; Magarelli DP; Koch CJ
    Am J Clin Oncol; 2001 Oct; 24(5):467-72. PubMed ID: 11586098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia is important in the biology and aggression of human glial brain tumors.
    Evans SM; Judy KD; Dunphy I; Jenkins WT; Hwang WT; Nelson PT; Lustig RA; Jenkins K; Magarelli DP; Hahn SM; Collins RA; Grady MS; Koch CJ
    Clin Cancer Res; 2004 Dec; 10(24):8177-84. PubMed ID: 15623592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunocytochemical labelling of aerobic and hypoxic mammalian cells using a platinated derivative of EF5.
    Matthews J; Adomat H; Farrell N; King P; Koch C; Lord E; Palcic B; Poulin N; Sangulin J; Skov K
    Br J Cancer Suppl; 1996 Jul; 27():S200-3. PubMed ID: 8763880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity.
    Koch CJ; Evans SM; Lord EM
    Br J Cancer; 1995 Oct; 72(4):869-74. PubMed ID: 7547233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
    Koch CJ; Hahn SM; Rockwell K; Covey JM; McKenna WG; Evans SM
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):177-87. PubMed ID: 11592338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
    Laughlin KM; Evans SM; Jenkins WT; Tracy M; Chan CY; Lord EM; Koch CJ
    J Pharmacol Exp Ther; 1996 May; 277(2):1049-57. PubMed ID: 8627516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
    Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
    Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.